<DOC>
	<DOCNO>NCT01947985</DOCNO>
	<brief_summary>This prospective cohort study provide information : characteristic Rivaroxaban use patient prescribe Rivaroxaban first time compare patient prescribe Acenocoumarol first time , occurrence intracranial haemorrhage , gastrointestinal urogenital bleeding , occurrence non-infective liver disease .</brief_summary>
	<brief_title>Study Rivaroxaban Use Potential Adverse Outcomes Routine Clinical Pratice ( Netherlands )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>All male female patient prescribe first time either Rivaroxaban standard care date market authorization rivaroxaban Dec 31 , 2017 Patients record dispense index drug year index date ( i.e . cohort entry ) , qualify cohort day exclude</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rivaroxaban</keyword>
	<keyword>Stroke Prevention Atrial Fibrillation ,</keyword>
	<keyword>Anticoagulants</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Observational</keyword>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>Secondary Prevention Acute Coronary Syndrome</keyword>
	<keyword>Intracranial Hemorrhages</keyword>
	<keyword>Gastrointestinal Hemorrhage</keyword>
</DOC>